Edition:
India

Vectura Group PLC (VEC.L)

VEC.L on London Stock Exchange

72.90GBp
22 Mar 2019
Change (% chg)

-1.00 (-1.35%)
Prev Close
73.90
Open
72.25
Day's High
75.75
Day's Low
72.05
Volume
576,244
Avg. Vol
912,107
52-wk High
107.80
52-wk Low
65.85

Chart for

About

Vectura Group plc is engaged in research, development and commercialization of therapeutic products and drug delivery systems for human use. The Company's products include Ultibro Breezhaler (European Union (EU) and Rest of World (RoW)) - LABA-LAMA; Seebri Breezhaler (EU and RoW) - LAMA; AirFluSal Forspiro (EU and RoW) -... (more)

Overall

Beta: 0.41
Market Cap(Mil.): £705.16
Shares Outstanding(Mil.): 679.34
Dividend: --
Yield (%): --

Financials

  VEC.L Industry Sector
P/E (TTM): -- 29.30 32.54
EPS (TTM): -- -- --
ROI: -- 14.23 13.82
ROE: -- 15.46 15.25

UPDATE 3-Vectura hopes new respiratory device will breathe life into business

* Forecasts 2018 adjusted core earnings above market forecasts

04 Jan 2019

UK drugmaker Vectura expects 2018 earnings to top market forecasts

Jan 3 British drugmaker Vectura Group Plc on Thursday predicted that its adjusted earnings in 2018 would top market expectations, helped in part by improving profit margins.

03 Jan 2019

Vectura drops severe asthma treatment after poor trial results

Britain's Vectura Group Plc will stop developing its treatment for severe uncontrolled asthma after a trial showed it failed to have a significant impact on the condition.

26 Nov 2018

UPDATE 1-Vectura to stop developing asthma treatment after late-stage failure

Nov 26 Vectura Group Plc will stop developing its treatment for severe uncontrolled asthma, the British drugmaker said on Monday, after the drug-device combination failed to meet the main goal of a late-stage study.

26 Nov 2018

Vectura to stop developing asthma treatment after late-stage failure

Nov 26 British drugmaker Vectura Group Plc said on Monday it would stop developing its treatment for severe uncontrolled asthma after the drug-device combination failed to meet the main goal of a late-stage study.

26 Nov 2018

Earnings vs. Estimates